Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Jun 21:15:1400891.
doi: 10.3389/fendo.2024.1400891. eCollection 2024.

Estimating the global prevalence of secondary hyperparathyroidism in patients with chronic kidney disease

Yichao Wang  1   2 , Jiaye Liu  1   2 , Yiqiao Fang  1   2 , Shengliang Zhou  1   3 , Xueting Liu  4 , Zhihui Li  1   2
Affiliations
Meta-Analysis

Estimating the global prevalence of secondary hyperparathyroidism in patients with chronic kidney disease

Yichao Wang et al. Front Endocrinol (Lausanne). .

Abstract

Background: Chronic kidney disease (CKD)-related secondary hyperparathyroidism (SHPT) is associated with higher morbidity and death. The goal of this study was to mine the SHPT data already available to do a meta-analysis on the global prevalence of SHPT caused by CKD.

Methods: Embase, Medline, Web of Science, Cochrane Central Databases, and Google Scholar were searched to identify studies on the prevalence of SHPT due to CKD from inception to November 2023. Pooled prevalence was calculated using the DerSimonian-Laird random effects model with a logit transformation.

Results: Twenty-one eligible studies involving 110977 patients were included. Our results revealed that the estimated global prevalence of SHPT due to CKD was 49.5% (95% CI 30.20-68.18), regardless of the diagnostic criteria. For subgroup analysis, Southern Asia (84.36%, 95% CI 79.35-88.34) had a significantly higher SHPT prevalence than other geographic regions. SHPT due to CKD was most prevalent in China (85.14%, 95% CI 81.74-88.00).

Conclusions: SHPT due to CKD is highly prevalent. This necessitates awareness and therapeutic approaches from primary care physicians, medical professionals, and health strategy authorities.

Systematic review registration: https://www.crd.york.ac.uk/PROSPERO, identifier CRD42024514007.

Keywords: chronic kidney disease; meta; meta-analysis; prevalence; secondary hyperparathyroidism.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flow diagram depicting the study selection.
Figure 2
Figure 2
Global prevalence of secondary hyperparathyroidism in patients with chronic kidney disease.
Figure 3
Figure 3
(A) Forest plots displaying prevalence in CKD patients. SHPT, secondary hyperparathyroidism; CKD, chronic kidney disease; and CI, confidence intervals. (B) Forest plots displaying the prevalence of SHPT stratified by continents. SHPT, secondary hyperparathyroidism; CKD, chronic kidney disease; and CI, confidence intervals. (C) Forest plots displaying the prevalence of SHPT stratified by countries and regions. SHPT, secondary hyperparathyroidism; CKD, chronic kidney disease; and CI, confidence intervals. (D) Forest plots displaying the prevalence of SHPT stratified by country income. SHPT, secondary hyperparathyroidism; CKD, chronic kidney disease; and CI, confidence intervals. (E) Forest plots displaying the prevalence of SHPT stratified by the development of countries. SHPT, secondary hyperparathyroidism; CKD, chronic kidney disease; and CI, confidence intervals. (F) Forest plots displaying the prevalence of SHPT stratified by study quality. SHPT, secondary hyperparathyroidism; CKD, chronic kidney disease; and CI, confidence intervals. (G) Forest plots displaying the prevalence of SHPT stratified by sex. SHPT, secondary hyperparathyroidism; CKD, chronic kidney disease; and CI, confidence intervals.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Murton M, Goff-Leggett D, Bobrowska A, Sanchez J, James G, Wittbrodt E, et al. . Burden of chronic kidney disease by KDIGO categories of glomerular filtration rate and albuminuria: A systematic review. Adv Ther. (2021) 38:180–200. doi: 10.1007/s12325-020-01568-8 - DOI - PMC - PubMed
    1. Rodríguez-Ortiz ME, Rodríguez M. Recent advances in understanding and managing secondary hyperparathyroidism in chronic kidney disease. F1000Res. (2020) 9:F1000 Faculty Rev–1077. doi: 10.12688/f1000research - DOI
    1. Wang F, Yang C, Long J, Zhao X, Tang W, Zhang D, et al. . Executive summary for the 2015 annual data report of the China kidney disease network (CK-NET). Kidney Int. (2019) 95:501–5. doi: 10.1016/j.kint.2018.11.011 - DOI - PubMed
    1. Sarnak MK, Amann K, Bangalore S, Cavalcante J, Charytan D, Craig J, et al. . Chronic kidney disease and coronary artery disease: JACC state-of-the-art review. J Am Coll Cardiol. (2019) 74(14):1823–38. doi: 10.1016/j.jacc.2019.08.1017 - DOI - PubMed
    1. Jankowski J, Floege J, Fliser D, Böhm M, Marx N. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation. (2021) 143:1157–72. doi: 10.1161/CIRCULATIONAHA.120.050686 - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources